瑞舒伐他汀对急性脑梗死患者血浆血管性假血友病因子和血栓调节蛋白水平的影响

摘要

Objective To discuss the effect of rosuvastatin on von wilebrand factor and plasma thrombomodu-lin ( TM) levels of acute cerebral infarction patients. Methods 76 cases of acute cerebral infarction patients from June 2012 to May 2013 in our hospital were divided into observation group and control group. The patients of the two groups were given basic treatment like intracranial pressure control,blood pressure and blood sugar maintenance,anti-platelet aggregation,brain cells nutrition etc. The patients of the observation group were given 100 mg rosuvastatin tablets per time,once daily for 2 weeks at the same time. The changes of vWF and TM levels in plasma of patients of the two groups were compared before and after medical treatment,and the curative effect and security were carried on as well. Results After 2 weeks′ medical treatment,the vWF and TM level of the two groups declined obviously than before treatment(P0. 05). Conclusion Rosuvastatin has reliable curative effect on acute cerebral infarction with high security,whose mechanism of action is to reduce vWF and TM level in plasma,protect and improve the vascular endothelial function.%目的：探讨瑞舒伐他汀对急性脑梗死患者血浆血管性假血友病因子( vWF)和血栓调节蛋白( TM)水平的影响。方法选择2012年6月至2013年5月我院收治的急性脑梗死患者76例,随机分为观察组和对照组,每组38例。两组患者均予以控制颅内压、维持血压、血糖、抗血小板聚集和营养脑细胞等治疗。观察组在此基础上加用瑞舒伐他汀片10 mg/次,1次/d,连用2周。观察两组患者治疗前后血浆vWF、TM水平变化,并观察临床疗效及安全性。结果治疗2周后,两组患者血浆vWF和TM水平较治疗前明显降低( P0．05)。结论瑞舒伐他汀治疗急性脑梗死临床疗效确切,安全性较好,其作用机制与其降低血浆vWF和TM水平,从而保护及改善患者的血管内皮功能密切相关。